Recombinant Mouse GPNMB protein (rFc Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg2814
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse GPNMB protein Lys23-Asn502 (Accession# Q99P91) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 93695 |
| Accession | Q99P91 |
| PredictedSize | 79.7 kDa |
| SDS-PAGE | 90-125 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
GPNMB is an endogenous type 1 transmembrane glycoprotein that was first described in 1995 as more highly expressed in low-metastatic melanoma cell lines . GPNMB is also known as Osteactivin, DC-HIL (dendritic cell heparan sulfate proteoglycan integrin-dependent ligand), and HGFIN (hematopoietic growth factor inducible neurokinin-1 type). While the name GPNMB is more broadly used, the name Osteoactivin is mostly used in studies with bones, while DC-HIL and HGFIN are commonly used in studies about the immune system and cells. GPNMB is constitutively expressed through most cell types and tissues, and its expression can be increased in cancer cells.
References:
1. Weterman MA, et al. Int J Cancer (1995) 60(1):73–81. 2. Taya M, et al. Steroids (2018) 133:102–7. 3. Saade M, et al. Front Immunol. 2021 May 12;12:674739.